NCT05020964Unknown2 期
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 68
- 主要终点
- objective response rate(ORR)
研究概览
简要总结
The hypothesis of this study is to discover the efficacy and safety of trastuzumab combined with pyrotinib in treating advanced breast cancer with HER2 positive, which is detected by digital PCR. It is a single-arm, multicenter phase II clinical study.
The purpose of this study is:
- To explore the Response rate (RR) and progression-free survival(PFS) and safety of patients with recurrent metastatic breast cancer who received trastuzumab combined with pyrotinib in positive plasma HER2 amplification detected by digital PCR.
- To explore the potential using of digital PCR in recurrent and metastatic breast cancer.
详细描述
The purpose of this study is:
- To explore the Response rate (RR) and progression-free survival(PFS) and safety of patients with recurrent metastatic breast cancer who received trastuzumab combined with pyrotinib in positive plasma HER2 amplification detected by digital PCR.
- To explore the potential using of digital PCR in recurrent and metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with recurrent or distant metastatic breast cancer whose primary tissue was negative for HER2 amplification, and newly diagnosed patients with stage IV breast cancer who were negative for HER2 amplification; All enrolled patients had previously received ≥ second-line therapy; Note: ① negative expression of HER2 refers to the primary tissue tested by IHC/FISH (clinical report), and the cell immunohistochemical staining intensity is 0,1 + or 2+, but negative by fluorescence in situ hybridization (FISH).
- •Age range 18-75, female;
- •Good physical strength: ECOG score 0-1;
- •Expected survival of more than 3 months;
- •The patient had no major organ dysfunction;Include: Routine blood The ANC acuity 1.5 x 109 / L;PLT acuity 90 x 109 / L;Hb 90 g/L or higher; Blood biochemical 1.5 x ULN TBIL or less;ALT and AST 2 x ULN or less;ALT and AST≤5×ULN in patients with liver metastases;BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); Heart colour to exceed LVEF 50% or higher;Fridericia adjusted QT interval (QTcF) for 12-lead electrocardiogram in men < 450 ms and in women < 470 ms.
- •Evaluable tumor lesions according to RECIST 1.1 criteria;
- •Voluntarily join the group, agree and sign the written informed consent.
排除标准
- •Patients who have previously received anti-HER2 therapy, or who have received a study drug or preparation/treatment (i.e., participating in another trial) within 4 weeks prior to enrollment;
- •Patients who are allergic to study drugs or unable to take them orally;Patients who refuse the medication regimen;
- •Serious dysfunction of vital organs (heart, liver, kidney);Clinically significant heart disease, i.e., New York Heart Association (NYHA) grade ⅲ - ⅳ heart failure or more severe congestive heart failure or severe arrhythmias requiring pharmacological intervention;Uncontrollable angina pectoris, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction within 6 months as confirmed by electrocardiogram (ECG);Previous history of organ transplantation, splenectomy;
- •Patients with other malignancies, except for cured non-melanoma skin cancers, cervical carcinoma in situ and other tumors that have been cured for at least 5 years;
- •Pregnant and lactating women (women of childbearing age are subject to pregnancy tests), fertile women with positive baseline pregnancy tests, or women of childbearing age who are unwilling to use effective contraception throughout the study period.;
- •In the active period of other acute infectious diseases or chronic infectious diseases;
- •A history of uncontrolled epilepsy, central nervous system disease or mental disorder;
- •Persons with disabilities of consciousness and other legal capacity or legal capacity limited;
- •A known history of human immunodeficiency virus;
- •Other conditions that the investigator considers inappropriate for the patient to participate in the study.
研究组 & 干预措施
Experimental Arm
Experimental
Trastuzumab and Pyrotinib
干预措施: Trastuzumab and Pyrotinib (Drug)
结局指标
主要结局
objective response rate(ORR)
时间窗: up to 1 year after the last patient enrolled
The ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR)
次要结局
- Progression free survival(PFS)(up to 1 year after the last patient enrolled)
- Incidence and Severity of adverse events(approximately 1.5 years)
研究者
Peng Yuan
Screening plasma HER2 amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib.
Chinese Academy of Medical Sciences
相似试验
尚未招募
不适用
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyHER2+ Advanced Breast Cancer Patients Progressing on TKI TherapyNCT05560308Tianjin Medical University Cancer Institute and Hospital50
招募中
2 期
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the BreastNode Negative Breast CancerMicrometastasis Breast CancerHormone Receptor Positive Breast CancerBreast CancerNCT04569747Dana-Farber Cancer Institute375
Unknown
2 期
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal WomenBreast CancerNCT02214004Gangnam Severance Hospital132
已完成
不适用
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.HER2 positive gastric cancerJPRN-UMIN000005792Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences30
尚未招募
2 期
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerHER2-positive Breast CancerNCT04158856xuexin he60